Given the central role of LAL in the etiology of atherosclerosis, scientists have hypothesized that supplementation with recombinant enzyme might also represent a valid strategy to halt disease progression (Du and Grabowski, 2004; Dubland and Francis, 2015; Figure 2). This evidence concerns the gene LIPA and atherosclerosis.